Cargando…

P1558: EARLY-START DEFERIPRONE IN INFANTS/YOUNG CHILDREN WITH TRANSFUSION-DEPENDENT BETA THALASSEMIA: EVIDENCE FOR IRON SHUTTLING TO TRANSFERRIN—RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (START)

Detalles Bibliográficos
Autores principales:	Tricta, F., Fradette, C., Temin, N., Rozova, A., Lee, D., Cabantchik, I.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429256/ http://dx.doi.org/10.1097/01.HS9.0000849088.46934.99

Ejemplares similares

S123: SAFETY AND EFFICACY OF EARLY-START DEFERIPRONE IN INFANTS AND YOUNG CHILDREN WITH BETA-THALASSEMIA (START STUDY)
por: Elalfy, M, et al.
Publicado: (2022)

P1442: PRACTICE-BASED EVIDENCE: LONG-TERM SAFETY COHORT OF DEFERIPRONE IN PATIENTS WITH SICKLE CELL DISEASE FROM THE US REGISTRY
por: Badawy, Sherif, et al.
Publicado: (2023)

The pharmacokinetic and safety profile of single-dose deferiprone in subjects with sickle cell disease
por: Soulières, Denis, et al.
Publicado: (2022)

P1511: EFFICACY AND SAFETY OF COMBINATION IRON CHELATION THERAPY WITH DEFERIPRONE AND DEFERASIROX IN PATIENTS WITH Β-THALASSEMIA MAJOR: A SYSTEMATIC LITERATURE REVIEW
por: Piga, A., et al.
Publicado: (2022)

Deferiprone for transfusional iron overload in sickle cell disease and other anemias: open-label study of up to 3 years
por: Elalfy, Mohsen S., et al.
Publicado: (2022)

Deferiprone‐induced agranulocytosis: 20 years of clinical observations
por: Tricta, Fernando, et al.
Publicado: (2016)

S120: RANDOMIZED CONTROLLED TRIAL OF THE EFFICACY AND SAFETY OF DEFERIPRONE: SUBGROUP ANALYSIS OF PEDIATRIC PATIENTS IN IRON-OVERLOADED PATIENTS WITH SICKLE CELL DISEASE AND OTHER ANEMIAS
por: Inusa, B, et al.
Publicado: (2022)

Deferiprone in the treatment of transfusion-dependent thalassemia: a review and perspective
por: Galanello, Renzo
Publicado: (2007)

S115: LONG-TERM EFFICACY AND SAFETY OF DEFERIPRONE FOR PATIENTS WITH SICKLE CELL DISEASE OR OTHER ANEMIAS
por: Inusa, B, et al.
Publicado: (2022)

Combination Iron Chelation Therapy with Deferiprone and Deferasirox in Iron-Overloaded Patients with Transfusion-Dependent β-Thalassemia Major
por: Karami, Hossein, et al.
Publicado: (2017)

Effects of renal impairment on the pharmacokinetics of orally administered deferiprone
por: Fradette, Caroline, et al.
Publicado: (2016)

Treating thalassemia major-related iron overload: the role of deferiprone
por: Berdoukas, Vasilios, et al.
Publicado: (2012)

MRI prospective survey on cardiac and hepatic iron in transfusion-dependent thalassemia intermedia patients treated with desferrioxamine, deferiprone and deferasirox
por: Meloni, Antonella, et al.
Publicado: (2015)

Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes
por: Kontoghiorghe, Christina N, et al.
Publicado: (2016)

The safety and acceptability of twice‐daily deferiprone for transfusional iron overload: A multicentre, open‐label, phase 2 study
por: Badawy, Sherif M., et al.
Publicado: (2021)

Prospective comparison on cardiac iron by MR in thalassemia major patients treated with combination deferipron-desferrioxamine versus deferipron and desferrioxamine in monoterapy
por: Pepe, Alessia, et al.
Publicado: (2011)

Efficacy and safety of combined oral iron chelation therapy with deferasirox and deferiprone in a patient with beta-thalassemia major and persistent iron overload
por: Alavi, Samin, et al.
Publicado: (2014)

A T2* MRI prospective survey on heart iron in thalassemia major patients treated with sequential deferiprone-desferrioxamine versus deferipron and desferrioxamine in monotherapy
por: Pepe, Alessia, et al.
Publicado: (2011)

Cardiac and hepatic iron and ejection fraction in thalassemia major: Multicentre prospective comparison of combined Deferiprone and Deferoxamine therapy against Deferiprone or Deferoxamine Monotherapy
por: Pepe, Alessia, et al.
Publicado: (2013)

Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson’s disease
por: Martin-Bastida, Antonio, et al.
Publicado: (2017)

Cost–Utility Analysis of Deferiprone for the Treatment of β-Thalassaemia Patients with Chronic Iron Overload: A UK Perspective
por: Bentley, Anthony, et al.
Publicado: (2013)

Correlation of Transferrin Saturation and Serum Ferritin with Bone Mass Density in Adult Transfusion Dependent Beta-Thalassemia Patients
por: Atmakusuma, Tubagus Djumhana, et al.
Publicado: (2021)

Effect of deferiprone or deferoxamine on right ventricular function in thalassemia major patients with myocardial iron overload
por: Smith, Gillian C, et al.
Publicado: (2011)

Erratum to: Cost–Utility Analysis of Deferiprone for the Treatment of β-Thalassaemia Patients with Chronic Iron Overload: A UK Perspective
por: Bentley, Anthony, et al.
Publicado: (2013)

Beta Thalassemia: New Therapeutic Options Beyond Transfusion and Iron Chelation
por: Motta, Irene, et al.
Publicado: (2020)

Deferiprone-induced arthropathy in thalassemia: MRI findings in a case
por: Chand, Gyan, et al.
Publicado: (2009)

Time to Start Delivering Iron Chelation Therapy in Newly Diagnosed Severe β-Thalassemia
por: Susanah, Susi, et al.
Publicado: (2020)

Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with nontransfusion-dependent thalassemia syndromes
por: Taher, Ali T, et al.
Publicado: (2016)

Estimates of the effect on hepatic iron of oral deferiprone compared with subcutaneous desferrioxamine for treatment of iron overload in thalassemia major: a systematic review
por: Caro, J Jaime, et al.
Publicado: (2002)

Correlations between Iron Load and CD4 in Adult Transfusion-Dependent Beta Thalassemia
por: Atmakusuma, Tubagus Djumhana, et al.
Publicado: (2021)

P1510: VAMIFEPORT PREVENTED THE FORMATION OF NON-TRANSFERRIN-BOUND IRON IN A MOUSE MODEL OF ΒETA-THALASSEMIA WITH BLOOD TRANSFUSIONS
por: Kalleda, N., et al.
Publicado: (2022)

Comparison of iron chelation effects of deferoxamine, deferasirox, and combination of deferoxamine and deferiprone on liver and cardiac T2* MRI in thalassemia maior
por: Ansari, Shahla, et al.
Publicado: (2017)

The transfusion management of beta thalassemia in the United States
por: Lal, Ashutosh, et al.
Publicado: (2021)

A T2* MRI prospective survey on heart iron in thalassemia major patients treated with sequential deferipron-desferrioxamine versus deferasirox
por: Pepe, Alessia, et al.
Publicado: (2011)

A T2* MRI prospective survey on heart iron in thalassemia major patients treated with deferasirox versus deferiprone and desferrioxamine in monotherapy
por: Pepe, Alessia, et al.
Publicado: (2011)

On improvement in ejection fraction with iron chelation in thalassemia major and the risk of future heart failure
por: Pennell, DJ, et al.
Publicado: (2011)

Ocular abnormalities in multi-transfused beta-thalassemia patients
por: Jafari, Reza, et al.
Publicado: (2015)

Quantum chemical analysis of the deferiprone–iron binding reaction
por: Wiwanitkit, Viroj
Publicado: (2006)

Effect of Iron-Chelator Deferiprone on the In Vitro Growth of Staphylococci
por: Kim, Choon-Mee, et al.
Publicado: (2009)

Transferrin receptor 2 (Tfr2) genetic deletion makes transfusion‐independent a murine model of transfusion‐dependent β‐thalassemia
por: Di Modica, Simona Maria, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_sb3kjkqo743ej0m07je9i1o1o7